AR039663A1 - Compuestos de 3,4-dihidroquinolin-2 (1h)-ona como antagonistas del receptor nr2b - Google Patents

Compuestos de 3,4-dihidroquinolin-2 (1h)-ona como antagonistas del receptor nr2b

Info

Publication number
AR039663A1
AR039663A1 ARP030101424A ARP030101424A AR039663A1 AR 039663 A1 AR039663 A1 AR 039663A1 AR P030101424 A ARP030101424 A AR P030101424A AR P030101424 A ARP030101424 A AR P030101424A AR 039663 A1 AR039663 A1 AR 039663A1
Authority
AR
Argentina
Prior art keywords
compound
dihydroquinolin
receptor antagonists
hydroxy
disease
Prior art date
Application number
ARP030101424A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR039663A1 publication Critical patent/AR039663A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP030101424A 2002-04-26 2003-04-24 Compuestos de 3,4-dihidroquinolin-2 (1h)-ona como antagonistas del receptor nr2b AR039663A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37593902P 2002-04-26 2002-04-26

Publications (1)

Publication Number Publication Date
AR039663A1 true AR039663A1 (es) 2005-03-02

Family

ID=29270728

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101424A AR039663A1 (es) 2002-04-26 2003-04-24 Compuestos de 3,4-dihidroquinolin-2 (1h)-ona como antagonistas del receptor nr2b

Country Status (15)

Country Link
US (1) US6713490B2 (enExample)
EP (1) EP1499606B8 (enExample)
JP (1) JP2005524696A (enExample)
AR (1) AR039663A1 (enExample)
AT (1) ATE325117T1 (enExample)
AU (1) AU2003219398A1 (enExample)
BR (1) BR0309778A (enExample)
CA (1) CA2483636A1 (enExample)
DE (1) DE60305026T2 (enExample)
ES (1) ES2258716T3 (enExample)
MX (1) MXPA04010549A (enExample)
PA (1) PA8572601A1 (enExample)
TW (1) TW200406402A (enExample)
UY (1) UY27776A1 (enExample)
WO (1) WO2003091241A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (en) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba and its derivatives for the treatment of pain
MXPA06003748A (es) * 2003-10-08 2006-06-14 Pfizer Compuestos de lactama condensada.
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
US20070185168A1 (en) * 2004-04-07 2007-08-09 Takai Haruki S Piperidine derivatives
HU226977B1 (en) * 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
AU2009296457A1 (en) 2008-09-27 2010-04-01 Taraxos Inc. Topical formulations for treatment of neuropathy
WO2010113109A1 (en) * 2009-03-31 2010-10-07 Link Research & Grants Corporation Treatment of tinnitus and associated auditory dysfunctions
WO2011145062A1 (en) 2010-05-21 2011-11-24 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
US20130230586A1 (en) 2010-10-02 2013-09-05 Link Research & Grants Corporation Treatment of Tinnitus and Related Auditory Dysfunctions
AU2013251079B2 (en) 2012-04-20 2017-03-23 Ucb Pharma S.A. Methods for treating Parkinson's disease
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902695A (en) 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
EP0554247B1 (en) 1990-05-10 2000-04-26 Pfizer Inc. Neuroprotective indolone and related derivatives
PL173618B1 (pl) 1992-10-30 1998-04-30 Pfizer Związki 6-[2-(4-hydroksy-4-fenylopiperydyno)-1-hydroksypropylo]-3,4-dihydro-2(1H)-chinolonowe
PA8525601A1 (es) 2000-08-21 2002-04-25 Hoffmann La Roche Profarmacos de (3s,4s)-4-bencil-1-[2-(4-hidroxi-bencenosulfonil)-etil]-piperidin-3-ol

Also Published As

Publication number Publication date
ES2258716T3 (es) 2006-09-01
WO2003091241A1 (en) 2003-11-06
US6713490B2 (en) 2004-03-30
DE60305026T2 (de) 2006-10-12
US20030216430A1 (en) 2003-11-20
PA8572601A1 (es) 2004-12-16
BR0309778A (pt) 2005-03-08
TW200406402A (en) 2004-05-01
JP2005524696A (ja) 2005-08-18
DE60305026D1 (de) 2006-06-08
AU2003219398A1 (en) 2003-11-10
UY27776A1 (es) 2003-11-28
EP1499606B1 (en) 2006-05-03
EP1499606A1 (en) 2005-01-26
MXPA04010549A (es) 2005-02-17
CA2483636A1 (en) 2003-11-06
ATE325117T1 (de) 2006-06-15
EP1499606B8 (en) 2006-08-30

Similar Documents

Publication Publication Date Title
JP7519221B2 (ja) 置換ピラゾロ［１，５－ａ］ピリミジンおよび医療疾患の治療におけるその使用
KR100311551B1 (ko) Aids 치료용 약제학적 배합물 중의 hiv 프로테아제 억제제
DE69925730T2 (de) 4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten
UY27776A1 (es) Compuestos de 3,4-dihidroquinolin-2( 1h ) -ona como antagonistas del receptor nr2b
AR049540A1 (es) Derivados de quinazolindiona como inhibidores del parp; metodos para su preparacion; composiciones farmaceuticas que los contienen como ingrediente activo y su uso en medicamentos para el tratamiento o prevencion del cancer.
US20250074873A1 (en) Compounds
WO2004014850A3 (en) Substituted aminopyrimidines as neurokinin antagonists
CL2011001263A1 (es) Compuestos derivados de pirimidinonas opcionalmente sustituidas; composicion farmaceutica que los comprende; y su uso como inhibidores de fosfodiesterasa 1 (pde1) para el tratamiento de enfermedades que involucran trastornos de la trayectoria intracelular del receptor de dopamina d1 como parkinson, alzheimer, depresion, enfermedad bipolar, hipertension, glaucoma.
KR20150114536A (ko) 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드
WO1996037226A2 (en) Combinations for the treatment of parkinsonism containing selective nmda antagonists
HRP20050876A2 (en) Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists
ATE453636T1 (de) Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
JP2007016011A (ja) 抗酸化活性を有する新規な含窒素ヘテロ環化合物、及び該化合物を含有する抗酸化薬
BR0312572A (pt) Derivados de azabiciclo como antagonistas de receptores muscarìnicos
AR066701A1 (es) 3-( imidazolil)- pirazolo {3,4-b] piridinas, composicion farmaceutica, proceso y uso en terapia
NZ600459A (en) Amyloid binding agents
DE60213629D1 (de) Piperidinverbindungen als muscarinantagonisten
WO2006113471A3 (en) N-alkyl-azacycloalkyl nmda/nr2b antagonists
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
PE20232046A1 (es) N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas
HRP20041048B1 (hr) POLIMORF 4-[2-[4-[1-(2-ETOKSIETIL)-1H-BENZIMIDAZOL-2-IL]-1-PIPERIDINIL]ETIL]-α, α- DIMETIL- BENZENOCTENE KISELINE
CL2009000491A1 (es) Compuestos derivados de 3-(4-(2-oxoindol)-piperidin)-pirrolidinas y 3-(4-benzo[b]imidazol)-piperidin)-pirrolidinas sustituidas proceso de preparacion; composicion farmaceutica; compuestos intermediarios; utiles en el tratamiento de la terapia del dolor, de enfermedades tales como alzheimer, ansiedad, depresion y glaucoma.
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
JPH06500099A (ja) Ｃｎｓ疾病の処置におけるヘテロ環状アミノ―アルコール化合物の使用
BRPI0409308A (pt) derivados azabiciclo como antagonistas de receptores muscarìnicos, composição farmacêutica e processo para sua preparação

Legal Events

Date Code Title Description
FB Suspension of granting procedure